Home > Medical Research Archives > Issue 149 > Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD): A General Overview and Approach in Clinical Practice
Published in the Medical Research Archives
Nov 2023 Issue
Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD): A General Overview and Approach in Clinical Practice
Published on Nov 29, 2023
DOI
Abstract
Metabolic dysfunction associated steatotic liver disease (MASLD) or previously known Non-alcoholic fatty liver disease (NAFLD) is a common condition with an estimated global prevalence of around 30%. It is becoming a public health concern due to its close association with type 2 diabetes mellitus and obesity. It is important to screen for those with inflammation and fibrosis to halt the progression to cirrhosis. Cirrhosis is associated with liver related complications and liver cancer. Currently, there are no targeted treatments for MASLD at this stage and most treatments are currently in clinical trials. The focus of treatment had been on managing underlying risk metabolic risk factors.
The purpose of this review to inform the readers of the change in the nomenclature from NAFLD to MASLD. This review will also focus on the background of MASLD, the pathogenesis as well as assessment and treatment of patients with MASLD.
Author info
Author Area
Have an article to submit?
Submission Guidelines
Submit a manuscript
Become a member